Dr. Mohammed Haseebuddin on PD-1 Expression in RCC

Video

Mohammed Haseebuddin, MD, a fellow in Urologic Oncology at Fox Chase Cancer Center, discusses the role of PD-1 expression in clear cell renal cell carcinoma (RCC).

An analysis looked at about 68 patients with clear cell RCC with flow cytometry and coordinated that with survival. These patients were compared with healthy non-cancer patients.

The analysis found that PD-1 expression on classical monocytes does demonstrate a poor prognosis—independent of grade, stage and other clinical variables, said Haseebuddin.

It has been shown, in the past, that PD-1 expression does decrease after surgery. The correlation that the analysis found between PD-1 expression and survival was in the preoperative setting, said Haseebuddin. If it can be determined which patients may have poor prognostic indicators, even before surgery, it is perhaps possible to identify those who would be better treated with immunotherapy.

Related Videos
Jeremy M. Pantin, MD, clinical director, Adult Transplant and Cellular Therapy Program, TriStar Centennial Medical Center, bone marrow transplant physician, Sarah Cannon Research Institute
Maria Hafez, MD, assistant professor, breast and sarcoma medical oncologist, director, Clinical Breast Cancer Research, Sidney Kimmel Medical College, Thomas Jefferson University
Zeynep Eroglu, MD
Sundar Jagannath, MBBS, director, Center of Excellence for Multiple Myeloma, professor of medicine (hematology and medical oncology), The Tisch Cancer Institute, Mount Sinai
Akriti Jain, MD
Raj Singh, MD
Gottfried Konecny, MD
Karim Chamie, MD, associate professor, urology, the University of California, Los Angeles
Mike Lattanzi, MD, medical oncologist, Texas Oncology
Ramez N. Eskander, MD